search
Back to results

New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery (HYALOENDOQoL)

Primary Purpose

Endometriosis, Adhesion, Quality of Life

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
40 cc HyaRegen NCH gel
40 cc sterile saline solution
Sponsored by
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Endometriosis

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • aged 18 to 45 years
  • undergoing laparoscopic surgery for suspicious of DIE
  • persistent pain irrespective to any medical treatment

Exclusion Criteria:

  • acute or severe infection
  • autoimmune disease
  • known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
  • concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery
  • clinical evidence of cancer
  • use of anticoagulant, fibrin glue, other thromboembolic agents
  • use of any other anti-adhesion agent during the procedure
  • patients with surgically diagnosed bowel involvement or need bowel resection
  • patients who want to receive any postoperative hormonal treatment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Experimental

    Arm Label

    Control

    HyaRegen NCH gel group

    Arm Description

    The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.

    In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.

    Outcomes

    Primary Outcome Measures

    The preoperative and postoperative 3rd and 6th month change of Visual Analogue Scale symptom score
    A validated form of VAS score was used and scored from 0: No pain to 10: the worst pain all in their lives in a likert fashion.

    Secondary Outcome Measures

    Short Form-12 Quality of Life
    A validated form of Short Form-12 Quality of Life that includes physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality (energy/fatigue) social functioning, role limitations due to emotional problems and mental health (psychological distress or wellbeing) were asked. The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). We used an online programme (https://www.orthotoolkit.com/sf-12) to calculate Short Form-12 Quality of Life total and sub-scale results. The maximum PCS-12 (Physical Score) is 55.57 and the maximum MCS-12 (Mental Score) is 60.75. The minimum PCS-12 (Physical Score) is 22.99 and the minimum MCS-12 (Mental Score) is 19.06.
    Endometriosis Health Profile (EHP-5)
    A validated form of Endometriosis Health Profile (EHP-5)

    Full Information

    First Posted
    July 13, 2019
    Last Updated
    March 11, 2021
    Sponsor
    Bakirkoy Dr. Sadi Konuk Research and Training Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04023383
    Brief Title
    New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery
    Acronym
    HYALOENDOQoL
    Official Title
    The Effect of New Cross Linked Hyaluronan Gel on Quality of Life of Patients After Deep Infiltrating Endometriosis Surgery: A Randomized Controlled Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    January 1, 2017 (Actual)
    Primary Completion Date
    January 1, 2019 (Actual)
    Study Completion Date
    June 1, 2019 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Bakirkoy Dr. Sadi Konuk Research and Training Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Hyaluronan, a glycosaminoglycan found in connective tissues and extracellular matrix, has been postulated to reduce postoperative adhesions, because of its unconditioned biological functions at tissue repair but unfortunately it has a fluid nature that causes rapid degradation, and it cannot effect long enough to work as an adhesion barrier.(10,11) For this reason a New cross-linked hyaluronan (NCH) gel, that has higher viscosity compared to natural hyaluronan has been developed by BioRegen Biomedical (Changzhou, Jiangsu, China). It has the ability for gradually absorption within 1 to 2 weeks in vivo, which are the acquired repair period and the critical time for adhesion formation. Although it seems evident that endometriosis has a serious impact on the daily Quality of Life of women; comparable data for the effect of adhesion barriers to patients who have had laparoscopic (Deep infiltrating endometriosis) DIE surgery is missing. Therefore a pilot randomised controlled study was conducted to evaluate the effect of NCH gel on short term quality of life in patients who had undergone laparoscopic surgery due to DIE.
    Detailed Description
    A prospective 1:1 randomised placebo-controlled study was conducted in our department during the study period January 2017-January 2019. All patients were included after obtaining written, signed informed consent before participating. All of the procedures were performed by the same surgery team who are experienced in minimally invasive (Deep infiltrating endometriosis) DIE surgery. The study protocol was approved by the local Ethics Committee of hospital (Approval number: 2017/04/35) 60 patients who were underwent for laparoscopic surgery for the treatment of deep infiltrating endometriosis without bowel involvement were recruited. The inclusion criteria for this study were as follows, aged 18 to 45 years, and undergoing laparoscopic surgery for suspicious of DIE and persistent pain irrespective to any medical treatment. Patients were booked for follow-up visits at the 3rd and 6th month postoperative months and wanted to fill the questionnaires. The exclusion criteria for the study were as; acute or severe infection, autoimmune disease, known/suspected intolerance or hypersensitivity to Hyaluronan or its derivatives, concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery, clinical evidence of cancer; use of anticoagulant, fibrin glue, other thromboembolic agents, or any other anti-adhesion agent during the procedure ,patients with surgically diagnosed bowel involvement or need bowel resection, and who want to receive any postoperative hormonal treatment. Participants were allowed to voluntarily withdraw from the trial for any reason at any time, and could be terminated by investigators owing to safety concerns, violations of inclusion/exclusion criteria, or pregnancy. Surgical procedure The patients were laid low lithotomy position under general anesthesia. Patients were assigned at random to either the NCH gel or control group in a 1:1 ratio through a computer based program. A standardised technic with 4 abdominal incision laparoscopic approach with 10 mm umbilical trocar for the optic camera and three 5 mm axillary ports for the surgical instruments were used. All of the surgeries initiated from exploring the pelvic cavity, identification of the ureters and dissection transection of the pelvic adhesion by 5 mm bipolar cautery used at 25 kw for coagulation mode and scissors. The incision was begun on the left pelvic sidewall just cephalad to the last deposit. The incision was then extended towards the uterus, lateral and parallel to the left uterosacral ligament. The uterosacral ligament was pushed medially and down and the healthy tissues including the ureter were pushed upwards and laterally away from the dissection. It then transected the right utero-sacral ligament and was continued along the right pelvic sidewall just lateral and above the right uterosacral ligament until it extends beyond all obvious deposits. All of the endometriotic foci was grasped and pulled then undercut and freed so that the whole lesion and a surrounding margin of healthy tissue was removed. After an extensive bleeding control the Patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures. The patients in the control group had 40 cc sterile saline solution compatible with the body temperature. Operators could not be blinded to treatment allocation, but the questionnaire assessors and the patients were blinded to treatment allocation. Pre and Postoperative assessment of pain and quality of life A dedicated research assisted in this study was asked the validated (visual analogue scale) VAS (dysmenorrhea, dyschezia, dyspareunia, dysuria, and pelvic pain), (endometriosis health profile-5) EHP-5 and (short form 12) SF-12 questionnaires before the day of the surgery. (12-14) A validated form of VAS score was used and scored from 0: No pain to 10: the worst pain all in their lives in a likert fashion. The VAS and (quality of life ) QoL questions were asked then in the 3rd and 6th month of during their follow up visits. A validated form of SF-12 that includes physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality (energy/fatigue) social functioning, role limitations due to emotional problems and mental health (psychological distress or wellbeing) were asked. The questions are scored and analysed using a statistical algorithm to give two scores: the physical component summary and the mental component summary. A validated form of EHP-5 questionnaire was used to determine endometriosis related QoL of the patients. EHP-5 consists of two parts: the first has a central questionnaire that evaluate five dimensions - pain, control and powerlessness, emotional well-being, social support, and self-image; and the second part measuring the areas of sexual intercourse, work, relationship with children, feelings about medical professional, treatment and infertility. Statistical analysis Data analysis was performed by using SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). A one-sample Kolmogorov-Smirnov test was performed to analyse the distribution of clinical variables. The frequency and percentage of the categorical variables and the mean, standard deviation, median and range values of the continuous and ordinal variables were presented. The study groups were compared using Student t test for parametric variables and Mann Whitney U test for the non-parametric variables. A post-hoc sample size calculation was performed via a two-sided Z test (α=0.05, β=0.20) for each study groups in order to obtain VAS scores as the primary outcome A p-value of < 0.05 was considered statistically significant for all calculations

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Endometriosis, Adhesion, Quality of Life, Surgery

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    60 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Control
    Arm Type
    Placebo Comparator
    Arm Description
    The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
    Arm Title
    HyaRegen NCH gel group
    Arm Type
    Experimental
    Arm Description
    In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
    Intervention Type
    Drug
    Intervention Name(s)
    40 cc HyaRegen NCH gel
    Other Intervention Name(s)
    bleeding control
    Intervention Description
    After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
    Intervention Type
    Drug
    Intervention Name(s)
    40 cc sterile saline solution
    Other Intervention Name(s)
    bleeding control
    Intervention Description
    After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
    Primary Outcome Measure Information:
    Title
    The preoperative and postoperative 3rd and 6th month change of Visual Analogue Scale symptom score
    Description
    A validated form of VAS score was used and scored from 0: No pain to 10: the worst pain all in their lives in a likert fashion.
    Time Frame
    The preoperative and postoperative 6th month change in Visual Analogue Scale symptom score
    Secondary Outcome Measure Information:
    Title
    Short Form-12 Quality of Life
    Description
    A validated form of Short Form-12 Quality of Life that includes physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality (energy/fatigue) social functioning, role limitations due to emotional problems and mental health (psychological distress or wellbeing) were asked. The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). We used an online programme (https://www.orthotoolkit.com/sf-12) to calculate Short Form-12 Quality of Life total and sub-scale results. The maximum PCS-12 (Physical Score) is 55.57 and the maximum MCS-12 (Mental Score) is 60.75. The minimum PCS-12 (Physical Score) is 22.99 and the minimum MCS-12 (Mental Score) is 19.06.
    Time Frame
    The preoperative and postoperative 3rd and 6th month change of Short Form-12 Quality of Life questions were recorded considering follow up visits.
    Title
    Endometriosis Health Profile (EHP-5)
    Description
    A validated form of Endometriosis Health Profile (EHP-5)
    Time Frame
    The preoperative and postoperative 3rd and 6th month change of A validated form of

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: aged 18 to 45 years undergoing laparoscopic surgery for suspicious of DIE persistent pain irrespective to any medical treatment Exclusion Criteria: acute or severe infection autoimmune disease known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery clinical evidence of cancer use of anticoagulant, fibrin glue, other thromboembolic agents use of any other anti-adhesion agent during the procedure patients with surgically diagnosed bowel involvement or need bowel resection patients who want to receive any postoperative hormonal treatment
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Murat Ekin, MD
    Organizational Affiliation
    Bakırkoy Dr. Sadi Konuk Training and Research Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    30244153
    Citation
    Arcoverde FVL, Andres MP, Borrelli GM, Barbosa PA, Abrao MS, Kho RM. Surgery for Endometriosis Improves Major Domains of Quality of Life: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2019 Feb;26(2):266-278. doi: 10.1016/j.jmig.2018.09.774. Epub 2018 Sep 20.
    Results Reference
    result

    Learn more about this trial

    New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery

    We'll reach out to this number within 24 hrs